Answer
Omjjara (momelotinib) is contraindicated during pregnancy because it may harm the foetus; if pregnancy occurs during treatment, treatment should be discontinued and the patient advised of the potential foetal hazard.
Sources for this answer
- Omjjara 150 mg film-coated tabletsGlaxoSmithKline UK · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 4Document updated
Sources checked